Nab-PTX and nab-PTX combined with immune checkpoint inhibitors for relapsed small cell lung cancer.

Abstract

8576 Background: Despite sensitivity to first-line chemotherapy, most small cell lung cancer (SCLC) patients experience disease progression after initial treatment. Nab-PTX showed comparable anti-tumor activity for relapsed SCLC. Whether immune checkpoint inhibitors (ICIs) combined with nab-PTX could improve clinical outcome for relapsed SCLC has not been fully evaluated. The aim of this study is to evaluate efficacy and safety of nab-PTX and nab-PTX combined with ICIs for relapsed SCLC. Methods: We retrospectively reviewed relapsed SCLC patients who were given nab-PTX (130mg/m2, day1,8 /Q3 weeks) or nab-PTX combined with ICIs (PD-1 or PD-L1), from Feb 2017 to Sep 2021. Clinical data were collected from electronic medical records. The clinical outcome, including progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method and standard Log-rank test. Results: A total of 56 patients with relapsed SCLC were included, 29 and 27 patients received nab-PTX (group A) and nab-PTX combined with ICIs (group B), respectively. Baseline characteristics were well balanced between the groups. Patient characteristics (group A: group B) were as follows; median age 57: 59, male 25(86.2%): 24(88.9%), heavy smoking 23(79.3%): 18(66.7%), ECOG-PS 1 19(65.5%) :19(70.4%), extensive disease 28(96.6%) :25(92.6%), liver metastasis 10(34.5%) :12(44.4%), brain metastasis 8(27.6%) :10(37%), refractory relapse 10(34.5%) :11(40.7%). ORR in group A and B were 17.2% vs 40.7%, and DCR in group A and B were 72.4% vs 66.7%, respectively. The median PFS and median OS were similar between group A and B (median PFS, 2.8months vs 3.2months; median OS, 9.3 months vs 11.0months). PFS and OS according baseline characteristics were showed in the table. Toxicity profile of group B was tolerable as well as group A. Conclusions: This retrospective study indicated nab-PTX combined with ICIs failure to improve clinical outcome for relapsed SCLC when compared with nab-PTX monotherapy.[Table: see text]